100+ Free CSOWM Practice Questions

Pass your Interdisciplinary Specialist Certification in Obesity and Weight Management exam on the first try — instant access, no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately

100+ Questions

100% Free

1 / 100

Question 1

Score: 0/0

Which obesity-related gene has the strongest documented effect size on monogenic, severe early-onset obesity and is the indication for setmelanotide therapy?

APOE4

MC4R (melanocortin-4 receptor) and POMC pathway variants

TCF7L2

FTO (fat mass and obesity associated)

to track

Same family resources

More CDR Dietetics Exams Prep

Continue through related practice pages, study guides, comparisons, and articles from the same exam family.

Practice Pages

CDR Registered Dietitian (RD) Practice200 questions CDR Registered Dietetic Technician (DTR) Practice199 questions CDR CSG Board Certified Specialist in Gerontological Nutrition Practice100 questions CDR CSO Board Certified Specialist in Oncology Nutrition Practice100 questions CDR CSP Board Certified Specialist in Pediatric Nutrition Practice100 questions CDR CSPCC Board Certified Specialist in Pediatric Critical Care Nutrition Practice100 questions

CDR DTR (NDTR) Exam Guide 2026: Pass Dietetic Tech (FREE)27 min read FREE CDN Exam Guide 2026: Pass CDR Renal Nutrition Cert26 min read

2026 Statistics

Key Facts: CSOWM Exam

150

Total Items

125 scored + 25 pretest

47%

Largest Domain Weight

Interventions

Multi

Eligibility

RDN, NDTR, RN, PA, MD, PhD, EP

BMI ≥30

ASMBS 2022 Bariatric Threshold

With metabolic disease

AAP 2023

Pediatric Obesity CPG

IHBLT ≥26 hrs over 1 yr

5 years

Certification Validity

CDR

The CSOWM (Interdisciplinary Specialist in Obesity and Weight Management) exam is administered by CDR and is open to RDNs, NDTRs, RNs, PAs, MDs, psychologists, and exercise physiologists. The exam consists of 150 multiple-choice items (125 scored + 25 pretest) over 3 hours. The fee is approximately $350-$500. Eligibility requires 2,000 hours of obesity/weight-management practice within the past 5 years. Interventions is the largest domain at 47%. Year-round PSI testing. Mastery of GLP-1/GIP pharmacotherapy and ASMBS 2022 bariatric criteria is essential.

Sample CSOWM Practice Questions

Try these sample questions to test your CSOWM exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A 48-year-old patient with a BMI of 32 kg/m2 asks about the underlying biology of obesity. Which statement BEST describes the role of leptin in established obesity?

A.Leptin levels are typically low in obesity, driving increased hunger

B.Most patients with obesity have leptin resistance, so high leptin fails to suppress appetite

C.Leptin is secreted by the stomach and stimulates ghrelin release

D.Leptin deficiency is the primary cause of obesity in over 50% of adults

Explanation: Leptin is produced by adipocytes in proportion to fat mass, so most adults with obesity have HIGH circulating leptin yet remain hungry, indicating central leptin resistance at the hypothalamus. True congenital leptin deficiency is rare (treated with metreleptin/setmelanotide pathway). Ghrelin (orexigenic) comes from the stomach, not leptin.

2Which gut hormone is MOST associated with the post-meal satiety signal that GLP-1 receptor agonists pharmacologically extend?

A.Ghrelin

B.Glucagon-like peptide-1 (GLP-1)

C.Cortisol

D.Adiponectin

Explanation: GLP-1 is an incretin secreted by intestinal L-cells after meals; it slows gastric emptying, enhances glucose-dependent insulin secretion, and signals satiety in the hypothalamus and brainstem. Semaglutide and liraglutide are pharmacologic GLP-1 receptor agonists that prolong this satiety signal. Ghrelin is orexigenic (hunger), cortisol is a stress hormone, and adiponectin is an insulin-sensitizing adipokine.

3A patient who lost 12% of body weight 6 months ago has regained 4 kg despite adherence to her plan. Which physiologic mechanism BEST explains weight regain after intentional weight loss?

A.A permanent increase in basal metabolic rate after weight loss

B.Compensatory increase in hunger hormones (ghrelin) and decrease in satiety hormones (PYY, GLP-1) plus reduced resting and non-resting energy expenditure

C.Increased leptin output from shrunken adipocytes

D.An autoimmune attack on remaining adipose tissue

Explanation: Sustained intentional weight loss triggers metabolic adaptation: ghrelin rises, PYY/GLP-1/CCK satiety signals fall, leptin drops disproportionately, and total energy expenditure declines beyond what is predicted by the new body mass (Sumithran 2011 NEJM). This neurohormonal defense of the prior 'set point' explains the high biological barrier to maintaining weight loss and supports long-term pharmacotherapy or surgical strategies.

4Which obesity-related gene has the strongest documented effect size on monogenic, severe early-onset obesity and is the indication for setmelanotide therapy?

A.FTO (fat mass and obesity associated)

B.MC4R (melanocortin-4 receptor) and POMC pathway variants

C.TCF7L2

D.APOE4

Explanation: Defects in the leptin-melanocortin pathway (POMC, PCSK1, LEPR, and MC4R) cause severe early-onset hyperphagic obesity. Setmelanotide is FDA-approved for POMC, PCSK1, and LEPR deficiency and Bardet-Biedl syndrome. FTO is the most common common-variant obesity association but with small per-allele effect (~1-1.5 kg). TCF7L2 is a T2DM risk gene; APOE4 is an Alzheimer/lipid gene.

5Per WHO and CDC adult criteria, a BMI of 36.4 kg/m2 in a non-Asian adult is classified as:

A.Overweight

B.Class I obesity

C.Class II obesity

D.Class III (severe) obesity

Explanation: Adult BMI categories: underweight <18.5; normal 18.5-24.9; overweight 25-29.9; class I obesity 30-34.9; class II obesity 35-39.9; class III obesity >=40. A BMI of 36.4 is class II. Class II with comorbidities or class III meets ASMBS surgical thresholds.

6A South Asian patient has a BMI of 24.5 kg/m2, waist circumference 92 cm, A1c 6.0%, and elevated triglycerides. According to WHO Asian-specific cutoffs, this patient is BEST classified as:

A.Healthy weight with no further action needed

B.Overweight by Asian-specific BMI criteria, with central adiposity and metabolic risk warranting intervention

C.Class I obesity by all global criteria

D.Underweight requiring nutritional repletion

Explanation: WHO endorses lower BMI cutoffs for Asian populations: overweight >=23 and obesity >=27.5, because cardiometabolic risk emerges at lower BMI. South Asian-specific waist circumference cutoffs are >=90 cm men / >=80 cm women. This patient meets Asian overweight + central adiposity + prediabetes criteria, justifying lifestyle and metabolic risk-factor intervention even though standard BMI is 'normal.'

7Which adult waist-circumference threshold indicates increased cardiometabolic risk per NHLBI/NIH guidelines (non-Asian populations)?

A.Men >88 cm (35 in); Women >102 cm (40 in)

B.Men >102 cm (40 in); Women >88 cm (35 in)

C.Men >94 cm (37 in); Women >80 cm (31 in)

D.Men >120 cm (47 in); Women >100 cm (39 in)

Explanation: NHLBI/NIH thresholds for elevated cardiometabolic risk are men >102 cm (40 in) and women >88 cm (35 in) in non-Asian populations. Asian-specific cutoffs are lower (>=90 cm men / >=80 cm women). Waist circumference complements BMI by capturing central adiposity, which is more strongly tied to T2DM and CVD risk.

8BMI may misclassify body fat status in all of the following EXCEPT:

A.An elite collegiate football lineman with BMI 33

B.A frail 82-year-old woman with sarcopenia and BMI 24

C.A South Asian adult with BMI 24 and central adiposity

D.A sedentary middle-aged accountant with BMI 33 and waist 110 cm

Explanation: BMI overestimates adiposity in muscular athletes, underestimates risk in older adults losing lean mass, and underestimates adiposity-driven risk in Asian populations. A sedentary adult with BMI 33 and waist 110 cm is correctly classified by BMI as having class I obesity with central adiposity; both measures agree, so no misclassification.

9Which body composition method is considered the clinical gold standard for measuring fat mass, lean mass, and bone mineral density?

A.Bioelectrical impedance analysis (BIA)

B.Skinfold calipers

C.Dual-energy X-ray absorptiometry (DXA)

D.Body mass index (BMI)

Explanation: DXA is considered the clinical gold standard, providing fat mass, lean mass, and bone density with low radiation. Hydrostatic weighing and air displacement plethysmography (BodPod) are research alternatives. BIA is portable and accessible but hydration-sensitive and less precise. BMI is a height-weight ratio, not a body composition tool.

10A multidisciplinary clinic uses Edmonton Obesity Staging System (EOSS) Stage 2 to classify a patient. What does EOSS Stage 2 indicate?

A.No apparent obesity-related risk factors or impairments

B.Subclinical risk factors only (e.g., borderline blood pressure)

C.Established obesity-related chronic disease (e.g., T2DM, HTN, OSA) with moderate functional limitation

D.End-stage disabling obesity-related conditions

Explanation: EOSS staging integrates medical, mental, and functional impact rather than BMI alone. Stage 0 = no risk; Stage 1 = subclinical; Stage 2 = established obesity-related chronic disease with moderate impairment; Stage 3 = end-organ damage with significant impairment; Stage 4 = severe disabling end-stage. EOSS predicts mortality more accurately than BMI alone.

About the CSOWM Exam

Interdisciplinary specialty certification administered by CDR for clinicians in obesity medicine and weight management. UNIQUE among CDR specialties: open to multiple disciplines (RDNs, NDTRs, RNs, PAs, MDs, psychologists, exercise physiologists). The CSOWM validates expertise across obesity pathophysiology, comprehensive assessment with screening for related comorbidities (T2DM, OSA, MASLD, depression, eating disorders), evidence-based interventions including the rapidly evolving GLP-1/GIP pharmacotherapy landscape (semaglutide, tirzepatide, setmelanotide), bariatric surgery with pre/post-op nutrition and lifelong supplementation, AAP 2023 pediatric obesity treatment guideline, and long-term continuation of care.

Questions

150 scored questions

Time Limit

3 hours

Passing Score

Scaled

Exam Fee

$350-$500 (CDR)

CSOWM Exam Content Outline

33%

Assessment

Pathophysiology, anthropometrics, EOSS/ABCD, comorbidity screening, MI/TTM

47%

Interventions

Diet, pharmacotherapy (GLP-1, tirzepatide), bariatric surgery, AAP 2023 pediatric, behavior change

20%

Continuation of Care

Interdisciplinary care, plateau response, post-bariatric follow-up, GLP-1 discontinuation, SDOH

How to Pass the CSOWM Exam

What You Need to Know

Passing score: Scaled
Exam length: 150 questions
Time limit: 3 hours
Exam fee: $350-$500

Keys to Passing

Complete 500+ practice questions
Score 80%+ consistently before scheduling
Focus on highest-weighted sections
Use our AI tutor for tough concepts

CSOWM Study Tips from Top Performers

1Master GLP-1 / GLP-1-GIP class: semaglutide 2.4 mg/wk SC (Wegovy, ~15% weight loss); tirzepatide (Zepbound, ~22%); AEs nausea/vomiting/diarrhea, pancreatitis (rare), C-cell tumor boxed warning (CI in personal/family MTC or MEN-2); titrate slowly to minimize GI

2Know ASMBS 2022 indications: BMI ≥35 OR ≥30 with metabolic disease (lower threshold than 1991 NIH). For adolescents: BMI ≥120% of 95th + comorbidity per AAP 2023

3Memorize bariatric supplements (lifelong post RYGB/SG): MVI with iron, B12 350 mcg PO daily or 1,000 mcg IM monthly, calcium citrate 1,500 mg/d, vit D 3,000 IU/d (titrate to level), iron 18-60 mg/d (women); thiamine 100 mg IV/IM for any persistent vomiting

4Understand weight regain biology: hormone shifts persist post-loss (decreased leptin, increased ghrelin, decreased PYY/GLP-1) for ≥1 year (Sumithran 2011 NEJM); justifies long-term pharmacotherapy and structured maintenance

5Know post-bariatric hypoglycemia (post-prandial, late, especially RYGB): related to incretin response; treat with low-glycemic + protein-paced + small frequent meals; acarbose adjunct

Frequently Asked Questions

Who is eligible for the CSOWM exam?

CSOWM is unique among CDR specialty exams in being interdisciplinary. Eligible disciplines include Registered Dietitians (RDNs), Nutrition and Dietetics Technicians Registered (NDTRs), Registered Nurses (RNs), Physician Assistants (PAs), Physicians (MDs/DOs), psychologists (PhDs/PsyDs), and exercise physiologists. All candidates need 2,000 hours of documented obesity/weight-management practice within the past 5 years.

What pharmacotherapy should I master?

All FDA-approved obesity meds: phentermine (short-term ≤12 wk, schedule IV); phentermine-topiramate ER (Qsymia, REMS for teratogenicity); naltrexone-bupropion (Contrave, CI seizure/MAOI/opioid); orlistat (lipase inhibitor, GI AEs, fat-soluble vit malabsorption); GLP-1 agonists liraglutide 3 mg (Saxenda) and semaglutide 2.4 mg/wk (Wegovy, ~15% weight loss); GLP-1/GIP tirzepatide (Zepbound, ~22% weight loss); setmelanotide for genetic obesity (POMC, PCSK1, LEPR, BBS); semaglutide and liraglutide approved for adolescents 12+.

What ASMBS bariatric surgery criteria are current?

Per ASMBS/IFSO 2022 indications: BMI ≥35 OR BMI ≥30 with metabolic disease (replacing the older NIH 1991 criteria of BMI ≥40 or ≥35 with comorbidity). Common procedures: sleeve gastrectomy (SG, ~70% of US procedures), Roux-en-Y gastric bypass (RYGB), biliopancreatic diversion with duodenal switch (BPD/DS, most weight loss + most malabsorption), one-anastomosis gastric bypass (OAGB, growing internationally). Lifelong supplementation required: B12, iron, calcium, vit D, plus thiamine for early post-op vomiting.

What does the AAP 2023 pediatric obesity guideline recommend?

AAP Clinical Practice Guideline 2023: intensive health behavior and lifestyle treatment (IHBLT) ≥26 contact hours over 1 year for ages ≥6 with BMI ≥85th percentile. Pharmacotherapy as adjunct for ≥12 years with BMI ≥95th percentile. Bariatric surgery referral for ages ≥13 years with BMI ≥120% of 95th percentile + significant comorbidity. This was a major shift from prior 'watchful waiting' approaches.

How should I study for the CSOWM exam?

Plan 60-100 hours over 8-12 weeks. Focus heavily on Interventions (47%) — master FDA-approved obesity pharmacotherapy (especially GLP-1/GIP class), ASMBS 2022 bariatric criteria + pre/post-op nutrition + lifelong supplementation, AAP 2023 pediatric obesity, motivational interviewing, behavior change theories (TTM, SCT). Cover Assessment (33%) with comorbidity screening tools and pathophysiology of weight regain biology (Sumithran 2011 NEJM).